BioTrove and Gene Express to Co-Market Novel Standardised Genetic Profiling Test
News Dec 02, 2008
Supported by a two-year National Institutes of Health (NIH) grant, the new profiling test combines BioTrove's OpenArray(R) nanofluidic polymerase chain reaction (PCR) technology platform, Gene Express standards for accurate and consistent PCR measurement, and the clinical expertise of the University of Rochester School of Medicine and Dentistry to create the Standardised NanoArray PCR (SNAP) gene expression profiling system - a novel method for consistent and accurate lung cancer risk analysis deployable to diagnostic laboratories or community hospitals.
Combining several high complexity, multi-gene diagnostic tests into a simple and easy-to-use diagnostic tool, the SNAP system is designed to both accelerate and control PCR analysis of biomarkers for lung cancer risk. The BioTrove OpenArray nanofluidic PCR platform enables large-scale analyses with minimal sample requirements, while the Gene Express Standardised RT PCR (StaRT-PCR) standards method controls for false negatives and false positives, and TaqMan(R) fluorogenic-labeled probes enable specific detection of PCR products, together providing the same quality and dynamic range of standard real-time quantitative PCR, but with simplified workflow and reduced sample requirements - an important consideration when dealing with limited clinical samples. The OpenArray system allows scientists to conduct up to 3,072 independent PCR analyses simultaneously on up to 144 samples in a plate the size of a microscope slide, while StaRT-PCR standards offer a novel method to control for consistent results.
"Our customers' need for viable gene expression analysis, in order to better evaluate patient risk, inspired us to bring together proven OpenArray PCR technology with Gene Express standards to control for consistent accurate results," said David Lester, Ph.D., Chief Technology Officer, Gene Express. "The result, our SNAP gene expression profiling system, simplifies and standardises laboratory workflow, as well as reduces reagent and sample requirements, making genetic profiling viable and translatable across diagnostic laboratories around the country and potentially around the world. This will be a significant contribution for the delivery of Personalised Medicine."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE